Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ: OBIO ) 5.080 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Orchestra BioMed Holdings, Inc. - Ordinary Shares Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update August 12, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors July 30, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances July 23, 2024 Jayme Strauss and Mike Kaswan join as Chief Clinical and Commercial Officer and Chief Financial Officer, respectively, as the company progresses toward FDA clearance From Precision Neuroscience Via GlobeNewswire Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 June 04, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed to Participate in Jefferies Global Healthcare Conference May 22, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update May 13, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents April 30, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 April 30, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update March 27, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors March 26, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting March 13, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed to Participate in Upcoming Investor Conferences March 07, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients March 06, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years February 26, 2024 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update November 13, 2023 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients September 19, 2023 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update August 10, 2023 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis August 08, 2023 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes June 26, 2023 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer June 07, 2023 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed to Present at the Jefferies Global Healthcare Conference June 01, 2023 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update May 12, 2023 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed to Present at Upcoming Investor Conferences March 07, 2023 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Orchestra BioMed Strengthens Senior Leadership Team February 07, 2023 From Orchestra BioMed Holdings, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.